The effect of controlling the ABC’s of diabetes on cardiovascular disease in a community-based endocrinology practice


Introduction: Large clinical trials demonstrate that glycemic, blood pressure, and cholesterol control lead to risk reduction in cardiovascular events. We determined whether A1c, blood pressure, and cholesterol control were associated with incident cardiovascular disease [CVD] in a community-based endocrinology practice over 10 years. Methods: 385 consecutive patients seen for diabetes management in a CBEP comprised the analysis cohort. To be included, a patient had ≥2 A1c, blood pressure, and LDLc measurements respectively without prevalent CVD. All patients were 18 years or older with a diagnosis of diabetes before or during calendar year 2000. Results: 17.6% of patients developed incident CVD over 10 years. After controlling for age, gender, and time, patients who improved their A1c to <7% during the time they spent in the practice had a 47% reduction in incident CVD [hazard rate = 0.53, 95% CI: 0.26 - 1.1]. Similar trends were observed for LDLc [27% reduction, hazard rate = 0.73, 95% CI: 0.3 - 1.8] and blood pressure control [35% reduction, hazard rate = 0.65, 95% CI: 0.33 - 1.3]. Additionally, patients who achieved all ABCSs at goal level at least once were 2.5x more likely not to develop incident CVD [hazard rate = 2.5, 95% CI: 1.2, 5.1] during their time in the practice. Conclusion: These results highlight the feasibility of achieving A1c, blood pressure, and cholesterol goals and demonstrate the significant impact that control has on incident CVD in a community-based endocrinology practice. Models of care that focus on prevention of complications through A1c, blood pressure, and cholesterol control may lead to decreased morbidity and mortality.

Share and Cite:

Varma, S. and Piatt, G. (2013) The effect of controlling the ABC’s of diabetes on cardiovascular disease in a community-based endocrinology practice. Journal of Diabetes Mellitus, 3, 202-207. doi: 10.4236/jdm.2013.34031.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] (2013) Heart Disease and Stroke Statistics—2013 Update. Circulation, e82-e92.
[2] The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications [DCCT/ EDIC] Study Research Group (2005) Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. New England Journal of Medicine, 353, 2643-2637.
[3] Holman, R.R., Paul, S.K. and Bethel, M.A. (2008) 10 year follow up of intensive glucose control in type 2 diabetes. New England Journal of Medicine, 359, 1577-1589. 0806470
[4] UKPDS 34. (1998) Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet, 352, 854-865.
[5] Sever, P.S., et al. (2012) Is plama renin activity a biomarker for the prediction of renal and cardiovascular outcomes in treated hypertensive patients: Observations from the Anglo-Scandinavian Cardiac Outcomes Trial [ASCOT]. European Heart Journal, 33, 2970-2979.
[6] Dahlof, B., Devereux, R.B., Kjeldsen, S.E., Julius, S., Beevers, G. and de Faire, U. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study [LIFE]: A randomised trial against atenolol. Lancet, 359, 995-1003.
[7] Heart Outcomes Prevention Evaluation [HOPE] Study Investigators (2000) Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the Hope study and MICRO-HOPE substudy. Lancet, 355, 253-259.
[8] Arnold, J.M.O., Yusuf, S., Young, J., et al. (2003) Prevention of heart failure in patients in the heart outcomes provention evaluation (HOPE) study. Circulation, 107, 1284-1290.
[9] Heart Protection Study Collaborative Group (2003) MRC/BHF Heart Protection Study of Cholesterol lowering with Simvastatin in 5963 people with diabetes. Lancet, 361, 2005-2016. 10.1016/S0140-6736(03)13636-7
[10] Pyorola, K., Pedersen, T.R., Kjekshus, J., Faergeman, O., Olsson, A.G. and Thorgiersson, G. (1997) Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. Diabetes Care, 20, 614-620.
[11] The Long-Term Intervention with Pravastatin in Ischaemic Disease [LIPID] (1998) Study group of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. New England Journal of Medicine, 339, 1349-1357.
[12] Treating to New Targets [TNT] Investigators (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine, 352, 1425-1435.
[13] Sacks, F.M., Tonkin, A.M., Craven, T., Pfeffer, M.A., Shepherd, J. and Keech, A. (2002) Coronary heart disease in patients with low ldl cholesterol. Circulation, 105, 1446-1452. 01.CIR.0000012918.84068.43
[14] Ford, E.S. (2011) Trends in the control of risk factors for cardiovascular disease among adults with diagnosed diabetes: Findings from the NHANES survey 1999-2008. Journal of Diabetes, 3, 337-347.
[15] Wong, K., et al. (2012) Comparison of demographic factors and cardiovascular risk factor control among us adults with type 2 diabetes by insulin treatment classification. Journal of Diabetes Complications, 26, 169-174.
[16] American Diabetes Association (2013) Standards of medical care in diabetes. Diabetes Care, 36, S11-S66.
[17] Varma, S., Boyle, L., Varma, M. and Piatt, G. (2008) Controlling the ABCs of diabetes in clinical practice: A community-based endocrinology practice experience. Diabetes Research and Clinical Practice, 80, 89-95.
[18] DECODE Study Group on Behalf of the European Diabetes Epidemiology Group (2001) Glucose tolerance and cardiovascular mortality. Comparison of fasting and 2-hour diagnostic criteria. Archives of Internal Medicine, 161, 397-405.
[19] Nathan, D.M. (2002) Initial management of glycemia in type 2 diabetes mellitus. New England Journal of Medicine, 347, 1342-1349.
[20] Olefsky, J.M. (2000) Treatment of insulin resistance with peroxisome proliferators activated receptor gamma agonist. Journal of Clinical Investigation, 106, 6467-6472. 10843
[21] Knoops, K.T., de Groot, L., Kromhout, D., Perrin, A., Varela, O. and Menotti, A. (2004) Mediterranean diet, lifestyle factors, and 10 year mortality in elderly European men and women. JAMA, 292, 1433-1439.
[22] Bolli, G.B. (2006) Physiological insulin replacement needed to limit hypoglycemia. Diabetes Care, 29, 1707-1709.
[23] Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E. and Parving, H.H. (2007) Effects of losaartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. New England Journal of Medicine, 345, 861-869.
[24] Colhoun, H.M., Betteridge, D.J., Durrington, P.N., Hitman, G.A., Neil, H. and Livingstone, S.J. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study [CARDS]. Lancet, 364, 685-696.
[25] Gaede, P., Lund-Anderson, H., Parving, H.H. and Pedersen, O. (2008) Effect of a multifactorial intervention on mortality in type 2 diabetes. New England Journal of Medicine, 358, 580-591.
[26] Stratton, I.M., Cull, C.A., Adler, A.I., Mathews, D.R., Neil, H.A.W. and Holman, R.R. (2006) Additive effects of glycemia and blood pressure exposure on risk of complications in type 2 diabetes UKPDS 75. Diabetologia, 49, 1761-1769.
[27] Skyler, J.S., Berganstal, R.B., Bonow, R.O., Buse, J., Deedwania, P., Gale, E.A.M., Howard, B.V., Kirkman, M.S., Kosiborod, M., Reaven, P. and Sherwin, R.S. (2009) Intensive glycemic control and the prevention of cardiovascular events: Implications of the ACCORD, ADVANCE, and VA Diabetes Trials. Diabetes Care, 32, 187-192.

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.